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Background: The aim of our study is to investigate correlations of TH1/TH2 cytokine gene poly-
morphisms and bronchoalveolar lavage fluid (BALF) cytokine values in interstitial lung diseases
(ILD).
Methods: In 16 sarcoidosis, 7 idiopathic pulmonary fibrosis (IPF) and 8 hypersensitivity pneu-
monitis (HP) patients we evaluated IL-1a, -1R, -1RA, -2, -4, -4Ra, -6, -10, -12, IFN-g, TGF-b1
and TNF-a gene polymorphisms in peripheral blood, and MCP-1,MIP-1a, MIP-1b, RANTES,
ENA-78, FGF, G-CSF, GM-CSF, IFN-g, IL-1a, IL-1RA, IL-1b, -2, -4, -5, -6, -8, -10, -17, TNF-a,
Tpo and VEGF values in BALF.
Results: We found higher TNF-a values in IL-1R pst 1970 TT homozygotes regardless of diag-
nosis (pZ 0.0126). In the sarcoidosis group IL-4Ra(þ1902)AA and IL-10(1082)G allele corre-
lated with higher BALF ENA-78 levels (pZ 0.0258, pZ 0.0230). In the HP group the IL-6
(174)CG and IL-6(nt565)AG correlated with higher ENA-78 BALF levels (pZ 0.0253). In the
IPF group the IL-1b þ3962 CC homozygotes had lower IL-1RA BALF values (pZ 0.046). BALF
chemokine values did not differ between ILD subgroups, except for IL-8, which was higher in
stage III sarcoidosis patients compared to stage I.
Conclusion: Our results show a probable influence of gene polymorphisms, namely IL-4Ra and
IL-10 on ENA-78 BALF levels in sarcoidosis, IL-6 on ENA-78 BALF levels in HP and IL-1-b on IL-1RA
BALF values in the IPF group. The TNF-a BALF values correlated with IL-1R pst 1970 gene poly-
morphisms.
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(AM) in the presence of prevalent TH2 type cytokines. ItIdiopathic pulmonary fibrosis (IPF), hypersensitivity pneu-
monitis (HP) and sarcoidosis belong to a large group of
interstitial lung diseases (ILDs) where an imbalance of
regulatory, profibrotic and antifibrotic cytokines and also
chemokines is supposed.
Among the most potent chemoattractants involved in
pathogenesis of these diseases belong regulated on acti-
vation, T-cell expressed and secreted (RANTES)/CC ligand
(CCL)5, macrophage inflammatory protein (MIP)-1a/CCL-3
and MIP-1b/CCL-4, interleukin (IL)-8/CXC ligand (CXCL)-8
and monocyte chemoattractant protein (MCP)-1/CCL2.
The latter is also involved in angiogenesis via inducing
the chemotaxis of endothelial cells and the formation of
blood vessels. Chemokines that promote angiogenesis
play a crucial role in all fibroproliferative disorders
including ILDs. This group of molecules includes the CXC
chemokine family members containing so-called ELR
motif such as IL-8/CXCL-8, epithelial neutrophil-activating
protein (ENA)-78/CXCL-5 and growth related genes
(GROs)-a, b, g/CXCL-1, -2, -3. The members of this
family not containing this motif are potent angiogenesis
inhibitors, i.e. monokine induced by interferon (IFN)-g
(MIG)/CXCL-9, IFN-g inducible protein (IP)-10/CXCL-10
and IFN-g inducible T-cell a chemoattractant (ITAC)/
CXCL-11.
Idiopathic pulmonary fibrosis (IPF) is a serious lung
disease with an unknown aetiology. The combination of
genetic predisposition and environmental influence is
supposed. Current data suggest that this disease is prob-
ably based on a pathologically accelerated growth rate and
dysfunction of lung tissue cells, which would normally
accomplish regular wound healing. The cellular immune
response, regardless of the initial mechanism of damage,
processes shifts to a so-called TH2 reaction, accompanied
by a relentless induction of mesenchymal growth during
wound healing. Experimental data suggest that the
immunomodulative properties of biological factors of
wound healing, such as some cytokines and their recep-
tors, mentioned previously, may be responsible for this
condition.1 An imbalance of angiogenic-vs-angiostatic
chemokines may contribute to the aberrant vasculogenesis
seen in IPF.2e4
Sarcoidosis is a multisystem inflammatory disease of
unknown aetiology characterized by epithelial granuloma
formation with accumulation of CD4þ T lymphocytes and
macrophages. An imbalance of cytokine and chemokine
production with a shift to so-called TH1 type immune
reaction is supposed. The situation is not so clear in later
phases of the disease, characterized by transition to
fibrosis, where the TH2 type and pro-fibrotic cytokines and
chemokines probably reach a dominant role.5,6
Hypersensitivity pneumonitis (HP) also belongs to the
granulomatous diseases group and has different clinical
stages in which different chemokines and cytokines prevail
according to the stage, from granulomatous to fibrotic, as
extreme poles of the disease phenotype.7e10
All the above-mentioned diseases probably share the
same pathogenetic mechanism of fibroproduction, which
could be the alternative activation of alveolar macrophagesappears that macrophage colony-stimulating factor (M-CSF)
can play a role in this alternative AM involvement and CCL2
production.11 These alternatively activated AMs induce an
increase of collagen production by fibroblasts. This process
seems to be mediated also by CCL18, which is overex-
pressed in the presence of interleukin IL-10, IL-4 and IL-
13.12,13 The study of Capelli et al supported the later
results, having revealed that CC chemokines, namely CCL2,
CCL3 and CCL4, were involved in the mechanisms of
pulmonary fibrosis.14 Zhu et al found that IL-13 is a potent
stimulator of MCPs and other CC chemokines, and docu-
mented the importance of MCP-1-CCR2 signalling in the
pathogenesis of the IL-13-induced pulmonary changes
which include pulmonary inflammation stimulation, hya-
luronic acid accumulation and tissue fibrosis.15 Antonioni
et al proved the existence of distinct angiogenic profiles
between IPF and sarcoidosis, indicating a potential
different role of CXC chemokines in the local immunologic
response in IPF and pulmonary sarcoidosis.16,17 The study of
Keane et al supported the IL-8 and IP-10 influence on
angiogenic activity regulation in IPF.18
There are more studies dealing with the expression of
chemokines and cytokines in BALF in ILDs but only a few
correlate the immunogenetic background with the BALF
cytokine and chemokine expression in these patients.
Navratilova et al studied MCP-1 2518 (A to G) single
nucleotide polymorphism (SNP) in Czech patients with
pulmonary sarcoidosis and found no difference in the SNP
distribution compared to the healthy population, but
a significantly higher proportion of G allele and GG geno-
type was observed in the patients with Lo¨fgren syndrome
(LS) compared to control subjects and patients without
LS.19 Japanese authors did not find any substantial role for
MCP-1 and MIP-1A genes in genetic predisposititon but
stated that these gene SNPs might be related to the
recruitment of monocytes/macrophages to the alveolar
spaces in sarcoidosis.20
We have described in our recent genetic studies the
potential role of IL-1, IL-4, IL-12 and IFN-g genes in the
pathogenesis and clinical presentation of sporadic IPF.
We have a pronounced suspicion of the pathogenic role of
IL-4 promoter region (IL-4 590, IL-4 33) polymorphisms
in IPF development.21 We have also found a correlation
of CD4þ and CD8þ T-cell counts in bronchoalveolar
lavage fluid (BALF) with IL-4 (1098) polymorphisms and
HLA DRþ T-cell counts with IL-1a (889) polymorphisms,
and a probable correlation of IL4Ra polymorphisms and
the high resolution computed tomography (HRCT)
alveolar score at the time of diagnosis. The interstitial
score, i.e. the fibrotic changes, seemed to be correlated
with IL-12 polymorphisms and the progression of lung
fibrosis correlated with IL-1RA, IL4Ra and IL-4 33
polymorphisms.22,23
The aim of our study is to investigate correlations of
TH1/TH2 cytokine gene polymorphisms and BALF cytokines
and chemokines levels in these patients. We hypothesize
that the polymorphisms, especially of regulatory cytokines,
could influence the expression of cytokines and chemokines
in lung tissue and BALF and thus cause the alternative
activation of AMs, which could lead to aberrant wound
healing with excessive fibroproduction.
Table 1 Demographic data and BAL cell counts in ILD
patients according to the groups.
Sarcoidosis
(16)
IPF (7) HP (8)
Mean age (years) 51.5
(SD 13.1)
63.7
(SD 9.4)
63.9
(SD 18.7)
Men/women 6/10 5/2 4/4
BAL lymphocyte
count in %
12 (0e71) 18 (4e72) 15 (0e78)
BAL neutrophil
count in %
3 (0e62) 6 (2e70) 7 (1e75)
BAL eosinophil
count in %
0 (0e4) 0 (0e27) 0 (0e6)
Smokers/Ex-smokers/
Non-smokers
5/2/9 1/4/2 1/1/6
BAL cell counts are stated in median values and a range.
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Study subjects
Sixteen sarcoidosis, 7 idiopathic pulmonary fibrosis (IPF)
and 8 hypersensitivity pneumonitis (HP) patients were
involved in our study. This study is a part of larger one
dealing with the genetic and immunological background of
ILDs. All patients with suspicion of ILD based on clinical
investigation, functional parameters and HRCT studies
undergo BALF investigation and genetic investigation of
peripheral blood. The diagnosis of specific ILD is arrived at
after stated procedures and in some patients also sup-
ported by transbronchial or videothoracoscopic biopsy.
Then the patients are sorted into subgroups according to
their definite diagnosis.
All seven patients with IPF (mean age 63.7 years, 5 men
and 2 women) were diagnosed according to the American
Thoracic Society (ATS)/European Respiratory Society (ERS)
consensus classification.24 We used the following criteria:
insidious onset of dyspnoea, bilateral basal crackles and
digital clubbing, restrictive ventilatory pattern and lowered
diffusion capacity for carbon monoxide, typical radiological
changes on high resolution computed tomography of the
lungs (HRCT) with prevailing fibrotic changes and granulo-
cytic bronchoalveolar lavage (BAL). The videothoracoscopic
lung biopsy was performed in four patients who did not
meet all the above-mentioned criteria, and the histopath-
ological investigation revealed the characteristic changes
of usual interstitial pneumonia (UIP).
The 16 sarcoidosis patients (mean age 51 years, 6 men
and 10 women) were diagnosed according to the American
Thoracic Society/European Respiratory Society/World
Association of Sarcoidosis and Granulomatous Disorders
statement on sarcoidosis, based on history, clinical symp-
toms, standard chest radiography, HRCT and laboratory
tests (serum angiotensin converting enzyme, calcaemia and
calciuria). Four patients had radiological stage I, 7 patients
stage II, and 5 patients stage III. All patients underwent
transbronchial biopsy or transbronchial lymph node punc-
ture or videothoracoscopic lung biopsy with histopatholog-
ical evidence supporting the diagnosis of sarcoidosis.
The diagnosis in 8 patients with HP (mean age 64 years,
4 men and 4 women) was based on history of exposition to
suspect antigen, typical clinical course, radiological
(HRCT) changes compatible with HP, BALF cell count and
the levels of specific IgG to the suspect antigen. The
diagnosis was supported with videothoracoscopic lung
biopsy in 3 patients. According to clinical stage of the
disease, with one exception all patients had chronic HP.
The patients all signed the Informed Consent Form
before submitting a blood sample for genotyping. The study
design and Informed Consent Form was approved by the
Central Ethical Committee of the Thomayer University
Hospital and the Institute for Clinical and Experimental
Medicine. Basic demographic data such as age and sex were
collected. The basic demographic data and BALF cell counts
are stated in Table 1. Interestingly the percentages of
lymphocytes were lower in patients with sarcoidosis and HP
than in those with IPF. This was probably caused by the fact
that the majority of HP patients had the chronic form of thedisease and also in the sarcoidosis group the majority of the
patients were stage I or III where the BALF lymphocytosis
need not be prominent (Table 1).
Methods
Polymorphisms in the promoter regions of the IL-1a, IL-1b,
interleukin-1 receptor (IL-1R), IL-1RA, IL-2, IL-4, IL-6, IL-10,
IL-12, TNF-a, IFN-g as well as polymorphisms in the trans-
lated regions of the transforming growth factor (TGF)-b,
IL-1b, IL-2, IL-4 and IL-4Ra genes were characterized.
Deoxyribonucleic acid (DNA) extraction
Ten millilitres of peripheral blood was collected in
ethylene-diamine-tetraacetic acid (EDTA) tubes and red
cell lysis buffer was added; after 20 min the tube was spun
for 10 min at 1300  g and the supernatant was removed.
White cell lysis buffer was then added to sediment with
proteinase and sodium dodecyl sulphate (SDS). The mixture
was incubated on a rotator for 18 h at 37 C. After incu-
bation 6 M NaCl and chloroform were added and mixed for
15 s before being centrifuged for 25 min at 1300  g. The
supernatant was added to 4 ml of absolute ethanol in
a clean tube. The precipitated DNA was removed, re-
suspended in sterile water and stored at 4 C.
Cytokine genotyping
We evaluated polymorphisms of thirteen different cytokine
genes utilizing CYTOKINE GENOTYPING KIT (Dynal, Biotech,
Norway). The test is designed as a polymerase chain reac-
tion (PCR) with sequence-specific primers. More closely,
each well of a 48 well tray contains specific primer pair for
amplifying desired unique sequence. Whole procedure was
performed according to the manufacture’s manual.
Obtained pattern of positive and negative PCR is docu-
mented and interpreted according to the manufacture’s
worksheet.
Bronchoalveolar lavage
BAL was performed during the fiberoptic bronchoscopy
under local anaesthesia. Five fractions of 50 ml of lukewarm
Table 2 Correlation of IL-1R pst 1970 polymorphisms and
TNF-a presence in BALF (pZ 0.0036).
No. of patients CC CT TT
Not measurable (%) 9 (81.8) 13 (81.2) 0 (0)
Measurable (%) 2 (18.2) 3 (18.8) 4 (100)
Table 3 Correlation of IL-4Ra(þ1902) polymorphisms with
BALF ENA-78 values in sarcoidosis (pZ 0.026).
Genotype (No. of patients) Mean value (SD)
AA (11) 35.744 (42.167)
AG (4) 64.228 (37.981)
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lobe where the bronchoscope was wedged. After instillation
the fluid was retrieved by syringe suction and put into sterile
containers. The first three parts were processed by ultra-
centrifugation and Giemsa staining for a cytological inves-
tigation and the fourth part was sent for flow cytometric
evaluation. The sample was determined to be valid if the
recovery was above 20 ml per fraction and the significant
admixture of polymorphic bronchial epithelial cells was not
found; otherwise the patient was not enrolled in our study.
The recovered BALF volume did not significantly differ
between enrolled patients. The supernatant was discarded
and stored frozen for later cytokine and chemokine
identification.
The BALF cytokine levels were investigated with Fluo-
rokine Multianalyte Profiling Kits with Luminex 100 plat-
form, Human cytokine panel A: MCP-1, MIP-1a, MIP-1b,
RANTES, ENA-78, FGF, G-CSF, GM-CSF, IFN-g, IL-1a, IL-
11RA, IL-1b, IL-2, -4, -5, -6, -8, -10, -17, TNF-a, thromo-
bopoietin (Tpo) and vascular endothelial growth factor
(VEGF) (R&D Systems, Inc. Minneapolis, USA), according to
the manufacturer’s protocol. The results were pronounced
in relative fluorescence units (RFU).
Statistical analysis
The genotype frequencies and allele carriage frequencies
were determined by direct counting. The basic statistical
characteristics, i.e. mean values, standard deviation and
median values, were counted from quantitative variables
(age, cell counts, cytokine values). The KruskaleWalllis test
with multiple comparisons was applied for comparison of
cytokine BALF values between the different ILD groups and
for correlation of BALF cytokine values with genotype in
different ILD groups. TNF-a values were measurable only in
some patients, thus we counted the values only as not
present (TNF-a not measurable) and present (measurable)
and stated as a percentage of the whole group. Pearson’s
chi-square and Fisher’s exact test were used for testing of
association of TNF-a presence in BALF with genotype.
Spearman’s correlation coefficient was applied for testing
of BALF chemokine values association with the sarcoidosis
stage. Statistical analysis was performed using MedCalc
statistical software. A p value of less than 0.05 was
considered significant.
Results
Not all of the investigated chemokines were detected in
BALF of the studied ILD patients. For instance, IFN-g was
detected only in one patient from the whole study group,
and IL-2, IL-4 and IL-10 in none of them. We have
considered for the statistical evaluation only the chemo-
kines whose values were detectable in BALF in a significant
number of patients. VEGF, IL-8, and IL-1RA were detected
in BALF in all of the patients. The VEGF BALF values
ranged from 0.29 to 182.84, IL-8 values from 3.98 to
335.43 and IL-1RA values from 61.53 to 5353.26. ENA-78
values were measurable in BALF of almost all patients
except three individuals and its values ranged from 0 to
154.54.TNF-a values ranged from 0 (undetectable) to 2.28 in
one of the patients with IPF. Five of 16 sarcoidosis patients
had measurable BALF TNF-a (range 0.15e1.43). One of
them was stage I, 3 stage II and only 1 stage III of the
disease, compared with 11 sarcoidosis patients with unde-
tected BALF TNF-a, where 6 of 11 had stage III of the
disease. In the IPF group only 2 of 7 patients had measur-
able TNF-a levels and in the HP group, where the majority
of patients had the chronic form of the disease, only 2 of 8
patients had detectable TNF-a BALF values. The cytokine
BALF values did not differ significantly between the
different ILD groups. TNF-a was identified only in some
patients and its presence in BALF did not differ significantly
between the ILD groups.
When we compared the presence of TNF-a in BALF with
cytokine genotype regardless of diagnosis, we found TNF-
a was significantly more frequently measurable in IL-1R pst
1970 TT homozygotes (pZ 0.0126) (Table 2). In the
sarcoidosis group, IL-4Ra(þ1902)AA and IL-10(1082)G
allele correlated with higher ENA-78 levels (pZ 0.0258,
pZ 0.0230) in BALF (Tables 3 and 4). In the HP group the IL-
6(174)CG and IL-6(nt565)AG both correlated with higher
ENA-78 BALF levels (pZ 0.0253 for both) (Tables 5 and 6).
In the IPF group the IL-1b þ3962 CC homozygotes had lower
IL-1RA values in BALF (pZ 0.046) (Table 7).
According to the sarcoidosis stage, we did not observe
statistically significant differences in BALF chemokine
values, except for IL-8, which was higher in patients with
stage III compared with stage I (rZ 0.574, p < 0.05)
(Fig. 1).
Discussion
TNF-a was identified only in some patients in our study and
its presence in BALF did not differ significantly between the
ILD groups. When we compared the presence of TNF-a in
BALF with cytokine genotype regardless of diagnosis, we
found TNF-a significantly more frequently measurable in IL-
1R pst 1970 TT homozygotes (pZ 0.0126) (Table 2). The
functional role of this polymorphism is not known to date,
but one can suppose the potential influence of the poly-
morphism on IL-1R signalling and inflammatory cascade
which could influence also TNF-a expression.
Table 4 Correlation of IL-10(1082) polymorphisms with
BALF ENA-78 values in sarcoidosis (pZ 0.023).
Genotype (No. of patients) Mean value (SD)
AA (5) 46.936 (60.714)
AG (8) 50.965 (28.934)
GG (3) 7.77 (12.771)
Table 6 Correlation of IL-6 nt 565 polymorphisms with
BALF ENA-78 values in HP (pZ 0.0253).
Genotype (No. of
patients)
Mean value (SD)
AG (5) 85.04 (27.418)
GG (3) 16.583 (23.400)
Cytokine genetics and BALF levels in ILD 777In the IPF group only 2 of 7 patients had measurable TNF-
a levels and in the HP group, where the majority of patients
had the chronic form of the disease, only 2 of 8 patients had
detectable TNF-a BALF values.
In the study of Tahanovich et al the group of sarcoidosis
patients with a poor clinical outcome was characterized by
a lower percentage of lymphocytes in BALF and rather small
amounts of TNF-a compared to those with a favourable
clinical outcome.25 In our study, 5 of 16 sarcoidosis patients
had measurable BALF TNF-a. One of them was stage I, 3
stage II, and only 1 stage III of the disease, compared with
those 11 sarcoidosis patients with undetected BALF TNF-a,
where 6 of 11 had stage III of the disease. Kuroki et al
showed on the model of TNF-deficient mice with bleomy-
cin-induced lung fibrosis that TNF also had an anti-
inflammatory function. He demonstrated persistent and
intense inflammation in TNF-deficient mice due to reduced
apoptosis of inflammatory cells and revealed that TNF is
essential for repressing pulmonary inflammation in bleo-
mycin-induced pneumopathy.26 These results support our
finding of measurable TNF-a levels mostly in patients with
prognostically favourable stages of sarcoidosis, though the
differences between the stages were not statistically
significant. According to the sarcoidosis stage, we observed
statistically significant differences in BALF chemokine
values only for IL-8, which was higher in patients with
stage III compared with stage I (Fig. 1). These results could
support the findings of Antoniou et al who described higher
IL-8 BALF levels in IPF patients, where the advanced lung
fibrosis is supposed, compared with sarcoidosis patients.16
IL-10 and TGF-b 1 are anti-inflammatory cytokines that
play important roles in the immunoregulatory processes of
numerous granulomatous diseases. In sarcoidosis poly-
morphisms within these cytokine genes were suspected of
modifying the course of the disorder.27 Previously the IL-10
1082 polymorphisms were proved to have an influence on
IL-10 production. Allele A was correlated with low IL-10
production and allele G with high IL-10 production.28 ENA-
78 and IL-8 BALF levels in IPF patients were found to be
significantly higher compared with sarcoidosis patients in
the study of Antoniou et al.16 In the study of Sugiyama et al
the ENA-78 BALF levels in patients with sarcoidosis wereTable 5 Correlation of IL-6(174) polymorphisms with
BALF ENA-78 values in HP (pZ 0.0253).
Genotype (No. of patients) Mean value (SD)
CG (5) 85.04 (27.418)
GG (3) 16.583 (23.400)significantly higher than those in control subjects and were
more increased in stage III sarcoidosis, showing that ENA-78
may be associated with lung parenchymal disease in
pulmonary sarcoidosis.29
In our study the cytokine BALF values did not differ
significantly between the different ILD groups. We suppose
that this finding could be ascribed to the greater number of
patients with advanced, i.e. fibrotic, disease in HP and
sarcoidosis groups. When correlating the gene poly-
morphisms with BALF cytokine levels IL-4Ra(þ1902)AA and
IL-10(1082)G allele correlated with higher BALF ENA-78
levels (pZ 0.0258, pZ 0.0230) in the sarcoidosis group
(Tables 3 and 4). This could prove the influence of geneti-
cally based IL-10 production up-regulation on increased
ENA-78 levels and thus on poor clinical outcome. Unfortu-
nately, the results of ENA-78 BALF values in the different
sarcoidosis stages did not support this idea in our study.
Nevertheless we might suppose that the clinical course of
the disease in those patients with higher ENA-78 might be
less favourable, but to date we have not carried out
a longitudinal study.
Lu et al have stated that the presence of high-expression
polymorphisms at position 174 of the IL-6 gene (allele G)
significantly increases the risk for bronchiolitis obliterans
syndrome development after lung transplantation.30 Grut-
ters et al hypothesized that the IL-6 174 C allele might
play a role in sarcoidosis severity or a progression towards
pulmonary fibrosis in a particular subgroup.31 In our study
the IL-6 polymorphisms (IL-6 174CG and IL-6 nt565 AG)
correlated with higher ENA-78 BALF levels only in the HP
group (pZ 0.0253 for both), which showed the possible
role also of IL-6 polymorphisms on ENA-78 production and
thus on the prognosis in HP (Tables 5 and 6). Nevertheless
we should be aware of the low number of HP patients in our
study.
Shimoji et al found that IL-1RA levels were decreased in
healthy smokers as well as IPF and sarcoidosis patients,
compared to healthy non-smokers, and suggested that
decreased expression of IL-1RA gene may contribute to the
development of chronic low-grade inflammation of the
lung.32 In our study, in the IPF group the IL-1b þ3962 CC
homozygotes had lower IL-1RA values in BALF (pZ 0.046),Table 7 Correlation of IL1b(þ3962) polymorphisms with
BALF IL-1RA values in IPF (pZ 0.046).
Genotype (No. of patients) Mean value (SD)
CC (3) 1079.3 (673.6)
CT (3) 4585.1 (1238.3)
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Figure 1 Correlation of BALF IL-8 levels and sarcoidosis stages.
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role in the pathogenesis of this disease (Table 7).
Conclusion
Our results show a probable influence of cytokine gene
polymorphisms on cytokine/chemokine levels in BALF,
especially for IL-4Ra and IL-10 on ENA-78 BALF levels in
sarcoidosis, IL-6 on ENA-78 BALF levels in HP, and IL-1b on
IL-1RA BALF values in IPF. The cytokine BALF values did not
differ significantly between the ILD subgroups, only within
the sarcoidosis subgroup did patients with stage III have
higher IL-8 BALF values as compared to stage I. TNF-a was
detectable only in some patients, mostly in those with
unadvanced sarcoidosis and BALF TNF-a detectability
correlated with IL-1R pst 1970 gene polymorphisms.
We suppose that cytokine gene polymorphisms, espe-
cially of so-called regulatory cytokines, probably influence
cytokine mRNA expression and thus also the level of
secreted protein and its functional status (activity). The
changes in cytokine levels could than influence chemokine
levels in target tissues and organs, i.e. lung, and form
a milieu enhancing inflammation and granuloma formation,
or on the other hand excessive fibroproduction in answer to
an unknown, probably mostly common, stimuli.
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